ALLEGRO-DVT
16.6.2022 15:32:14 CEST | Business Wire | Press release
Allegro DVT, the leading provider of video processing silicon IPs and video compliance streams, has announced that its D310 AV1 Decoder silicon IP now supports 12-bit sample size and 4:4:4 chroma sub-sampling. Emerging applications such as cloud-gaming, automotive and screen mirroring will directedly benefit from these new features to provide a superior video quality and preserve the finest details in video content.
Allegro DVT’s D310 IP is part of the D3x0 highly customizable silicon IP family that builds on a scalable architecture allowing picture resolutions ranging from HD/4K up to 8K/16K while providing support for sample sizes from 8-bit to 12-bit and chroma subsampling from 4:0:0 up to 4:4:4.
Allegro DVT is able to address the growing demand of state-of-the-art video processing blocks in advanced System-on-Chips (SoCs) by providing highly configurable decoding IP cores supporting a variety of selectable codecs. In addition to AV1, the D3x0 family also supports JPEG, H.264, HEVC, VP9 and VVC video formats. Furthermore, its unique and scalable architecture approach offers the best trade-off between silicon size and power consumption keeping the operating frequency of the resulting solutions at a reasonable level to allow physical implementations in mainstream and cost-efficient process node technologies.
The D310 is immediately available with a comprehensive documentation and SW drivers for a smooth integration into video SoCs.
Nouar Hamze, CEO, commented “We are committed to supporting the AV1 ecosystem and accelerating the adoption of this promising video codec. Our D310 product is the very first AV1 Decoder IP to provide support for 12-bit pixel size and 4:4:4 chroma subsampling format. These high-end features will extend the breadth of target applications to includes advanced HDR, cloud-gaming, wireless display and automotive in which preserving video quality is of utmost importance. This IP represents the culmination of our engineering and marketing effort in bringing together the requirements of vastly different applications and generating optimal solutions in terms of power, performance, and area.”
About Allegro DVT
Allegro DVT, headquartered in Grenoble/France with offices in Belfast/Northern Ireland and Beijing/China, is a world leading provider of digital video technology solutions including compliance streams and video codec semiconductor IPs focused on the H.264/AVC, H.265/HEVC, AVS2, AVS3, VP9, AV1 and VVC standards.
For more information, visit our website or contact us
View source version on businesswire.com: https://www.businesswire.com/news/home/20220616005011/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
L&T Technology Services Launches Ainfonix™ 4.0 to Unlock Engineering Intelligence Across Process Industries30.6.2026 12:45:00 CEST | Press release
The enterprise AI platform turns millions of engineering artifacts that run a plant into accurate, decision-ready data, delivering up to 85% extraction accuracy and full, audit-ready traceability L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in Engineering Intelligence Solutions & ER&D Consulting Services, today announced the launch of Ainfonix™ 4.0, a next-generation Engineering Intelligence platform for process industries. Unveiled at EI Live, LTTS’ flagship event that brings together analysts, industry leaders and engineering experts, Ainfonix™ 4.0 marks an important step in the company’s Enterprise AI and Engineering Intelligence strategy. As industrial enterprises accelerate AI adoption, decades of engineering knowledge remain trapped in fragmented drawings, specifications and technical records across disparate systems. Without trusted and accessible engineering data, organizations struggle to realize the full value of AI, automation and digital transformation
Klick Health Acquires Oxford PharmaGenesis, Bringing Together Unsurpassed Scientific-to-Commercial Capabilities for Life Sciences Clients30.6.2026 12:03:00 CEST | Press release
Bonded by breakthroughs and a laser focus on their people and clients, leading independent agencies join forces to deliver accelerated commercial success through broadened medical affairs and communications, market access, and RWE/HEOR offerings; the most advanced degree holders; expanded global reach; and the best workplace culture around Focused on taking life sciences companies into the future, Klick Health today announced its acquisition of Oxford PharmaGenesis, the market-leading HealthScience communications consultancy renowned for its scientific and medical expertise, as well as value and market access consulting throughout Europe, Asia-Pacific, and North America. Today’s news brings together two of the leading independent agencies in life sciences. With Oxford PharmaGenesis’ expertise across medical affairs and market access, and Klick's strength in commercial strategy, medical, creative, digital, analytics, and experience design, they can deliver an unparalleled scientific-to-
BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma30.6.2026 12:00:00 CEST | Press release
Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p<0.0001), meeting the primary endpoint of PFSMANGROVE is the first Phase 3 trial to advance a new chemotherapy-free standard in frontline MCL, potentially allowing patients freedom from the burden of years of infusionsFull results from MANGROVE, including efficacy and safety, will be presented at an upcoming medical meeting; global regulatory submissions are planned for 2H 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306; NCT04002297) evaluating foundational BTK inhibitor BRUKINSA® (zanubrutinib) plus rituximab versus bendamustine plus rituximab (BR) in adult patients with previously untreated mantle cell lymphoma (MCL). MANGROVE is the first Phase 3, global, randomized trial to evaluate a BTK inhibitor-based chemotherapy-
Hytera Debuts SC700 Smart 4G Body Camera at CCW 202630.6.2026 11:30:00 CEST | Press release
Hytera, a leading global provider of critical communications technologies and solutions, officially debuted its SC700 Smart 4G Body Camera at Critical Communications World (CCW) 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630283236/en/ Hytera's latest SC700 Smart 4G Body Camera Public safety operations are increasingly moving toward real-time, connected workflows, where communication, video, and situational awareness are integrated to support a faster and more coordinated response in the field. The SC700 is designed to support this shift. It enables live video, location sharing and push-to-talk communication, helping connect frontline officers with control rooms. Integrated with Hytera HyTalk PoC System, it also supports communication across broadband and PMR users to improve coordination across teams. It also features Intelligent Scene Aware, which can detect abnormal situations such as man down, inactivity, or
Global Database Launches Regis, an AI Assistant for Live Company Registry Data30.6.2026 11:13:00 CEST | Press release
Regis gives business users a ChatGPT-like experience for company research, compliance checks, ownership discovery, financial analysis, and prospect list building — powered by live data from official government registries Global Database today announced the launch of Regis, a new AI assistant designed to answer business questions using live company data from official government registries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630229011/en/ Unlike general-purpose AI tools that rely on training data or open web sources, Regis is connected to Global Database’s structured company intelligence platform, covering more than 600 million company profiles, sourced from over 400 government registries across more than 200 countries. For more than a decade, Global Database has been collecting, structuring, and maintaining company data directly from government registries around the world. With the launch of Regis, the company
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom